{"id":35841,"date":"2015-05-08T08:06:55","date_gmt":"2015-05-08T12:06:55","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=35841"},"modified":"2015-05-08T08:06:55","modified_gmt":"2015-05-08T12:06:55","slug":"after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841","title":{"rendered":"After Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Spyryx Biosciences Sets Updates About Cystic Fibrosis"},"content":{"rendered":"<p style=\"text-align: justify;\">With the help of extraordinary findings and growth in relation with Cystic Fibrosis, <strong>Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)<\/strong> has made a lot of money and grabbed everyone&#8217;s attention in the recent past. But it&#8217;s Spyryx Biosciences that has come up with the latest updates. As per the <a href=\"http:\/\/www.fiercebiotech.com\/story\/spyryx-biosciences-raises-18m-novel-take-cystic-fibrosis\/2015-05-07\">reports<\/a>, Spyryx claims to have discovered a way to treat all types of CF with a single therapy. It has recently raised $18 million to initiate advance research in this field and reach a meaningful conclusion.<\/p>\n<p style=\"text-align: justify;\"><strong>Spyryx&#8217;s Achievements So Far:<\/strong><\/p>\n<p style=\"text-align: justify;\">The company was founded in 2013 with an objective to unearth some of the rarest issues in the bioscience field. It focuses on fleshing out the extraordinary work of Robert Tarran, Professor, University of North Carolina. Tarran is the one who located an important link between the airway dehydration and the regulatory protein SPLUNC1. Scientists believe that airway dehydration leads to the deadly pulmonary symptoms of CF.<\/p>\n<p style=\"text-align: justify;\">As per the reports, the human body makes use of SPLUNC1 to modulate the quantity of fluid that is absorbed in the airways. It also crafts a peptide therapy that mimics the effects of protein. Spyryx strongly believes that it has hit upon a never-before-used way to reverse all the characteristic dehydration of CF. The doctors have used a lot of targeted therapies like Kalydeco of Vertex to get rid of hundreds of problems in the past. These therapies have a good scope in the future as well.<\/p>\n<p style=\"text-align: justify;\">The only problem with such therapies is that they work on those patients those genetic mutations. The number of such patients is not more than 5%, which is a sign of worry for the health experts. It forms a perfect ground for any such therapy that can get rid of all types of CFs singlehandedly. Spyryx hopes that it will manage to come up with a feasible solution for different types of CFs in the future.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>With the help of extraordinary findings and growth in relation with Cystic Fibrosis, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has made a lot of money and grabbed [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":33033,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[11433,11434,11432],"stock_ticker":[],"class_list":["post-35841","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqvrtx","tag-spyryx-biosciences","tag-vertex-pharmaceuticals-incorporated-nasdaqvrtx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>After Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Spyryx Biosciences Sets Updates About Cystic Fibrosis - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"After Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Spyryx Biosciences Sets Updates About Cystic Fibrosis - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"With the help of extraordinary findings and growth in relation with Cystic Fibrosis, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has made a lot of money and grabbed [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-08T12:06:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"259\" \/>\n\t<meta property=\"og:image:height\" content=\"194\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"After Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Spyryx Biosciences Sets Updates About Cystic Fibrosis\",\"datePublished\":\"2015-05-08T12:06:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841\"},\"wordCount\":328,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\",\"keywords\":[\"NASDAQ:VRTX\",\"Spyryx Biosciences\",\"Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841\",\"name\":\"After Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Spyryx Biosciences Sets Updates About Cystic Fibrosis - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\",\"datePublished\":\"2015-05-08T12:06:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\",\"width\":259,\"height\":194},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"After Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Spyryx Biosciences Sets Updates About Cystic Fibrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"After Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Spyryx Biosciences Sets Updates About Cystic Fibrosis - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841","og_locale":"en_US","og_type":"article","og_title":"After Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Spyryx Biosciences Sets Updates About Cystic Fibrosis - Wall Street PR","og_description":"With the help of extraordinary findings and growth in relation with Cystic Fibrosis, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has made a lot of money and grabbed [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-05-08T12:06:55+00:00","og_image":[{"width":259,"height":194,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"After Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Spyryx Biosciences Sets Updates About Cystic Fibrosis","datePublished":"2015-05-08T12:06:55+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841"},"wordCount":328,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","keywords":["NASDAQ:VRTX","Spyryx Biosciences","Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841","url":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841","name":"After Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Spyryx Biosciences Sets Updates About Cystic Fibrosis - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","datePublished":"2015-05-08T12:06:55+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","width":259,"height":194},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/after-vertex-pharmaceuticals-incorporated-nasdaqvrtx-spyryx-biosciences-sets-updates-about-cystic-fibrosis-35841#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"After Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Spyryx Biosciences Sets Updates About Cystic Fibrosis"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=35841"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35841\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/33033"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=35841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=35841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=35841"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=35841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}